76360-82-2Relevant articles and documents
Development of radioiodinated pyrimidinopyridone derivatives as targeted imaging probes of activated p38α for single photon emission computed tomography
Hashimoto, Tomoyuki,Kondo, Naoya,Hirata, Masahiko,Temma, Takashi
, p. 1293 - 1304 (2021/08/23)
Objective: p38α, a member of the mitogen-activated protein kinase superfamily, is ubiquitously expressed in a variety of mammalian cells. Activated p38α induces inflammatory responses to external stimuli, suggesting that non-invasive detection of activate
Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma
Liu, Haibo,Niu, Deqiang,Tham Sjin, Robert Tjin,Dubrovskiy, Alex,Zhu, Zhendong,Mcdonald, Joseph J.,Fahnoe, Kelly,Wang, Zhigang,Munson, Mark,Scholte, Andrew,Barrague, Matthieu,Fitzgerald, Maria,Liu, Jinyu,Kothe, Michael,Sun, Fangxian,Murtie, Joshua,Ge, Jie,Rocnik, Jennifer,Harvey, Darren,Ospina, Beatriz,Perron, Keli,Zheng, Gang,Shehu, Elvis,D'Agostino, Laura Akullian
supporting information, p. 1899 - 1904 (2020/11/09)
Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer and is one of the most common forms of cancer worldwide. Aberrant signaling of the FGF19-FGFR4 pathway leads to HCC in mice and is hypothesized to be a driver in FGF19 amplifie
FGFR4 kinase inhibitor, preparation method and uses thereof
-
Paragraph 0203-0204; 0206-0207, (2020/04/17)
The present invention relates to a compound represented by a formula (I), or a pharmaceutically acceptable salt, a solvate, a polymorph or an isomer thereof, and uses in preparation of drugs for treatment of FGFR4 mediated diseases.